PCD may affect 10-times more than was thought

19 October 2008

The orphan status genetic disease, primary ciliary dyskinesia, could affect 10-times more children than was previously thought, according to data from a study presented at the European Respiratory Society conference in Berlin, Germany.

A task force set up by the Society believes PCD may occur in between one in 3,000 and one in 10,000 children in Europe, far exceeding the previous one in 30,000 estimate, after an unprecedented study into the incidence and treatment of the disease in the area.

Surveys filled in by 210 practitioners, covering 1,071 patients in 24 countries, illustrated a startling disparity in care practices. The average age at which the disease was diagnosed was: 5.5 years in western and northern Europe; seven years in southern Europe; and 8.5 years in eastern Europe. 72% of treatment centers provide regularly quarterly check-ups for PCD sufferers, but 4% only offer an annual appointment, whereas 2% see patients only on request.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight